Product Images Capecitabine

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Capecitabine NDC 68001-487 by Bluepoint Laboratories, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Capecitabine Tablets USP 150mg (NDC 68001 487 06) Rev 0921 Intas Pharmez Site

Capecitabine Tablets USP 150mg (NDC 68001 487 06) Rev 0921 Intas Pharmez Site

Capecitabine Tablets 150mg 60's Bottle Label - capecitabine 150 label

Capecitabine Tablets 150mg 60's Bottle Label - capecitabine 150 label

Each tablet contains 150mg of Capecitabine, a cytotoxic agent. The tablets should be swallowed whole with water and should not be crushed or cut. It is recommended to store the tablets in tight containers and in controlled room temperature between 15°C - 30°C. For proper dosage and prescribing information, please refer to the accompanying insert. These tablets are manufactured by Intas Pharmaceuticals Limited, Ahmedabad-382 210, INDIA, for BluePoint Laboratories. Total quantity in one package is 60 Tablets.*

Capecitabine Tablets 500mg 120's Bottle Label - capecitabine 500 label

Capecitabine Tablets 500mg 120's Bottle Label - capecitabine 500 label

Figure 1 - capecitabine fig1

Figure 1 - capecitabine fig1

Figure 2 - capecitabine fig2

Figure 2 - capecitabine fig2

The text is not readable.*

Figure 3 - capecitabine fig3

Figure 3 - capecitabine fig3

The provided text represents a chart displaying estimated probabilities for a certain treatment (namely, 5-FU + Leucovorin or Capecitabine at 1250mg/sqm e daily) administered intermittently over a period of time. The x-axis represents time in days, with values ranging from 0 to 1500. The y-axis represents estimated probability percentages, with values ranging from 0.0 to 10.0. The chart indicates that the treatment's effectiveness is expected to improve over time, with higher probabilities associated with longer periods of treatment.*

Figure 4 - capecitabine fig4

Figure 4 - capecitabine fig4

Figure 5 - capecitabine fig5

Figure 5 - capecitabine fig5

Chemical Structure - capecitabine met path

Chemical Structure - capecitabine met path

Chemical Structure - capecitabine str

Chemical Structure - capecitabine str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.